Michael Bailey: Don’t take yourself too seriously
Florian Lordick Elected ESMO President 2029–2030
AI-Based Histopathology Analysis Predicts Checkpoint Inhibitor Response in Advanced Melanoma
OncoDaily Ambassadors at ASCO 2026
CHRYSALIS-2 Trail at ASCO 2026: Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLC
Betamethasone Ointment to Prevent Severe Oral Mucositis During Head and Neck Chemoradiotherapy
Adjuvant Radiotherapy vs Observation Following Curative Surgery for Early-Stage Oral Squamous Cell Carcinoma
Douglas Flora: The Calculus of Hope - 45,000 People, One Mission
Enter RS and clinical context to view RS category and trial-aligned interpretation for early HR+/HER2- breast cancer.
This calculator is intended for ER/PR+ HER2- breast cancer only
TAILORx (Node-negative): Demonstrated that chemotherapy provides minimal to no benefit for most patients with RS 11-25. For patients ≤50 years, some benefit may be seen in RS 16-25.
RxPONDER (Node-positive, 1-3 nodes): Showed that postmenopausal patients with RS 0-25 did not benefit from chemotherapy. Premenopausal patients derived benefit regardless of RS.
RS Categories:
Low
0-10
Intermediate
11-25
High
26-100
